2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions

View by Date

Monday, September 23, 2019

1:45pm-3:15pm: The Preferences of Patients with Parkinson’s Disease and their Family Members for Place of End-of-Life Care

R. Kozáková, R. Bužgová, M. Bar, M. škutová, P. Ressner, P. Bártová (Ostrava, Czech Republic)

Quality of Life · Les Muses Terrace, Level 3

1:45pm-3:15pm: The progression rate of sporadic adult-onset cerebellar ataxia : 1-year follow up study

PW. Ko, HW. Lee, K. Kang (Daegu, Republic of Korea)

Ataxia · Les Muses, Level 3

1:45pm-3:15pm: The relationship between sound pressure level (SPL) and speech intelligibility in Parkinson’s disease following intensive speech treatment: LSVT LOUD and LSVT ARTIC

L. Ramig, E. Levy, M. Chang, K. Forrest, G. Moya-Gale (Boulder, CO, USA)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: The relationship between the motor onset and the asymmetry of motor symptoms in patients with Parkinson’s Disease

Y. Trufanov, N. Svyrydova, V. Svistun, I. Harkava, H. Bondarenko, N. Zhhilova (Kyiv, Ukraine)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: The Representativity of PSP patients included in clinical trials

LL. Mariani, R. Guimarães-Costa, D. Grabli, B. Letoullec, F. Cormier, B. Degos, B. Dubois, M. Vidailhet, L. Lacomblez, JC. Corvol (Paris, France)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: The Roche HD Natural History Study – an external comparator by design

G. Hooper, G. Palermo, F. Hlavac, C. Finnegan, E. Frick, L. Boak, R. Doody, S. Schobel (Welwyn Garden City, United Kingdom)

Huntington’s Disease · Agora 3 West, Level 3

1:45pm-3:15pm: The role of attention in functional movement disorders

A. Huys, P. Haggard, K. Bhatia, M. Edwards (London, United Kingdom)

Functional (Psychogenic) Movement Disorders · Les Muses Terrace, Level 3

1:45pm-3:15pm: The role of dysfunctional attentional processing in isolated minor hallucinations in Parkinson’s disease

H. Bejr-Kasem, J. Pagonabarraga, S. Martínez-Horta, F. Ruiz-Martínez, F. Bernasconi, F. Sampedro, J. Marín-Lahoz, A. Horta-Barba, I. Aracil-Bolaños, B. Pascual-Sedano, O. Blanke, J. Kulisevsky (Barcelona, Spain)

Psychiatric Manifestations · Les Muses Terrace, Level 3

1:45pm-3:15pm: The Role of Dysfunctional BDNF in Remodeling the Parkinsonian Striatum Following Dopamine Neuron Grafting in CRISPR rs6265 Rats

N. Mercado, J. Stancati, T. Collier, C. Sortwell, I. Sandoval, C. Kemp, B. Daley, M. Duffy, K. Steece-Collier (Grand Rapids, MI, USA)

Gene and Cell-Based Therapies · Les Muses Terrace, Level 3

1:45pm-3:15pm: The role of genetic modifiers in Parkinson’s disease-associated LRRK2-G2019S mutation

T. Courtin, G. Ianello, H. Bertrand, S. Benromdhan, C. Tesson, C. Mhiri, JC. Corvol, S. Lesage, A. Brice (Paris, France)

Genetics · Les Muses Terrace, Level 3